Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
ALNYLAM PHARMA RG (NQ: ALNY)
105.93 USD  -0.33 (-0.31%)
Official Closing Price  /  Updated: 8:00 PM EDT, Jul 20, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 418,391
Open 106.33
Bid (Size) 104.00 (600)
Ask (Size) 109.00 (200)
Prev. Close 106.26
Today's Range 105.75 - 108.07
52wk Range 70.76 - 153.99
Shares Outstanding 100,522,411
Dividend Yield N/A
Performance
YTD
-19.66%
-19.66%
1 Month
+0.64%
+0.64%
3 Month
+8.67%
+8.67%
6 Month
-15.14%
-15.14%
1 Year
+31.57%
+31.57%
Top News
More News
Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the pivotal study results from the APOLLO Phase 3 trial of patisiran were published online... Read More
from Business Wire News Releases
Report: Developing Opportunities within Valvoline, Parker Drilling, Dean Foods, BioPharmX, Hasbro, and Alnylam Pharmaceuticals — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Valvoline Inc. (NYSE:VVV),... Read More
from GlobeNewswire News Releases
More News
Read More
Why This Biotech Company 'Dominates' Its Rival In Drug Study
from Investor's Business Daily
Alnylam to Host Fifth Annual “RNAi Roundtable” Webcast Series
from Business Wire News Releases
Alnylam Expands Senior Leadership Team with Two Key Appointments
from Business Wire News Releases
This Biotech Could Rival Amgen, Regeneron With Cheaper Cholesterol Drug
from Investor's Business Daily
Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology
from Business Wire News Releases
Over 700 Alnylam Employees Volunteer at the Company’s 4th Annual “Helping Hands” Community Service Day
from Business Wire News Releases
Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
from Business Wire News Releases
Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyret
from Business Wire News Releases
Alnylam Pharmaceuticals Larger Than S&P 500 Component Perrigo Company
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.